ObjectiveTo systematically review the association between angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) therapy and digestive system neoplasms.MethodsPubMed, EMbase, The Cochrane Library, CNKI, WanFang Data, VIP and CBM databases were searched from inception to February 2017 to collect studies about ACEIs/ARBs therapy and risk of digestive system neoplasms or survival of digestive system neoplasms patients. Two reviewers independently screened the literature, extracted the data and evaluated the risk of bias of included studies, then meta-analysis was performed using Stata 12.0 software.ResultsA total of 21 articles including 32 studies were included. The results of meta-analysis showed that ACEIs/ARBs therapy could reduce the risk of colorectal cancer (OR=0.92, 95%CI 0.86 to 0.99, P=0.023), but there were no relationships between ACEIs/ARBs therapy and the risk of liver cancer or gastric cancer. ACEIs/ARBs therapy could improve the survival of colorectal cancer patients (HR=0.79, 95%CI 0.63 to 0.98, P=0.031), but there was no association between ACEIs/ARBs therapy and the survival of pancreatic cancer patients (HR=0.75, 95%CI 0.50 to 1.13, P=0.165).ConclusionACEIs/ARBs therapy may reduce the risk of colorectal cancer, as well as improve the survival of colorectal cancer patients, but there are no significant relationships between ACEIs/ARBs therapy and the risk or the survival of other digestive system neoplasms, such as liver cancer, gastric cancer and pancreatic cancer. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusion.
Objectives To evaluate the relationships between the Scavenger Receptor Class B1 (SCARB1) polymorphisms and susceptibility of cardiovascular diseases (CVDs). Methods Databases including PubMed, Web of Science, CNKI, WanFang Data and VIP were searched from inception to December 31st 2017 to collect case-control studies on relationships between Scavenger Receptor Class B1 (SCARB1) polymorphisms and susceptibility of CVDs. Paper screening, data extraction and assessment of risk of bias were carried out. Meta-analysis was then conducted by Stata 12.0 software. Results In total, 12 studies relevant to SCARB1 rs5888C/T, rs4238001 G/A and rs10846744 G/C polymorphisms were included. Meta-analysis showed that there was no significant association between the rs5888 C/T polymorphism and susceptibility of CVDs (C vs. T: OR=0.97, 95%CI 0.86 to 1.09, P=0.627), neither for the rs4238001 G/A (G vs. A: OR=0.87, 95%CI 0.64 to 1.17, P=0.344). However, the rs10846744 G/C polymorphism was significantly associated with CVDs risk (G vs. C: OR=1.30, 95%CI 1.11 to 1.52, P=0.001). Subgroup analysis showed that, for non-Asian subjects, there was a significant association between the rs5888 C/T polymorphism and susceptibility of CVDs (C vs. T: OR=0.82, 95% CI 0.68 to 0.99, P=0.040). Conclusions SCARB1 rs10864744 G/C polymorphism could be associated with risk of CVDs. Considering the quantity and quality limitation of the included studies, the conclusion has to be verified by more large-scale high quality studies.
ObjectiveTo systematically review the impact of ACEI/ARB (angiotensin converting enzyme inhibitor/ angiotensin receptor antagonist) treatment on the clinical outcomes of Chinese patients with COVID-19 infections. MethodsPubMed, EMbase, Web of Science, The Cochrane Library, CNKI, WanFang Data, and VIP databases were electronically searched to collect cohort studies on the impact of the treatment with ACEI/ARB on the clinical outcomes of Chinese patients with COVID-19 infections from January 2020 to January 2022. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of the included studies. Then, meta-analysis was performed using RevMan 5.3 software. ResultsA total of 17 cohort studies involving 4 912 subjects were included. The results of meta-analysis showed that patients who were prescribed ACEI/ARB had shorter hospital stays (SMD=−0.28, 95%CI −0.46 to −0.11, P=0.002) and a lower mortality rate (OR=0.47, 95%CI 0.36 to 0.62, P<0.000 01) than patients who did not take ACEI/ARB. ConclusionCurrent evidence shows that the use of ACEI/ARB drugs can improve the clinical prognosis of Chinese patients with COVID-19 infections. Due to the limited quality and quantity of the included studies, more high-quality studies are needed to verify the above conclusion.
Purpose To investigate the protective effect ofldquo;haw drink compoundrdquo;against carbon disulfide (CS2)toxic retinal damage． Methods Thirty healthy white adult New Zealand rabbits were divided at random into 3 groups:the normal control group,the exposure control group and the treatment group．The experimental rabbits were contaminated by inhaling CS2 for 3 continuoues hours in 6 consecutive days in a week for totaly 3 weeks．The rabbits in the treatment group were given haw drink compound before containation．After 3 weeks of the experiment,the retinal tissues of the rabbits were examined with light microscope and transmissing electronmicroscope(TEM). Results The ultrastructures of the retinal tissues of the exposure control group were more abnormal than those of the treatment group and the normal control group．TEM showed that every layer cell of the retinal in the exposure control group showed apparent degenerative changes ,but that in the treatment group showed apparent degenerative changes,but that in the treatment group was nomal．The light microscpic picture showed that the inner segments and the outer segments of photoreceptors construction were destroyed,the nerve fiber layer was loose and ganglion celles vacuolated in the retinat of the exposure control group．TEM showed that The photorecepter synapses were vacuolated,the postsynaptic space became wider and the synaptic sticks disappered． Conclusion How drink compound can improve the tolerance to CS2 toxicity in inducing the retinal damage of rabbits. (Chin J Ocul Fundus Dis, 1999, 15: )
An efficient organocatalytic cascade reaction has been developed involving a Michael-hemiaminalization relay for the asymmetric synthesis of spiropiperidinone derivatives : bearing adjacent quaternary and tertiary chiral centers via LUMO or HOMO activation. Importantly, this methodology demonstrates that applying distinct activation modes to different substrates in the same reaction can diverge diastereoselectivity. To our knowledge, this is also one of the few published cases of primary amine catalytic [3 + 3] cycloaddition reactions involving alpha-branched beta-ketoamides.